Enphase Energy (ENPH) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in June, followed ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

Moderna's Spikevax vaccine is the first to receive full approval for use in children aged 6 months to 11 years with a high-risk health issue.

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Firms like Moderna that are rapidly adopting AI and will have a higher mix of AI software robots to humans in the future ...